Long noncoding RNA BLACAT1 modulates ABCB1 to promote oxaliplatin resistance of gastric cancer via sponging miR-361

Wu, Xiao Hou; Zheng, Yuanzheng; Han, Bin; Dong, Xuefan

doi:10.1016/j.biopha.2018.01.130

Cited by 93 publications

(66 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ye et al (19) identified that lncRNA BLACAT1 promotes the proliferation, migration, and invasion of non-small cell lung cancer through sponging miR-144. Wu et al (20) revealed that lncRNA BLACAT1 modulates ABCB1 to promote oxaliplatin resistance of gastric cancer via sponging miR-361. However, Liao et al (21) demonstrated that lncRNA BLACAT1 is downregulated in papillary thyroid carcinoma and could act as a suppressor gene in tumor progression.…”

Section: Discussionmentioning

confidence: 99%

Long non‑coding RNA BLACAT1 promotes the proliferation and invasion of glioma cells via Wnt/β‑catenin signaling

et al. 2019

Exp Ther Med

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) are hypothesized to regulate numerous biological behaviors in human cancers. The present study aimed to explore the roles of lncRNA bladder cancer associated transcript 1 (BLACAT1) in glioma. The expression of BLACAT1 in glioma tissues and cell lines was determined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). CCK-8 assay, colony formation assay, wound healing assay and Transwell invasion assay were used to explore the roles of BLACAT1 in glioma cells. RT-qPCR and western blot analysis were used to determine the BLACAT1 molecular mechanism. The findings demonstrated that lncRNA BLACAT1 was overexpressed in glioma tissues and cell lines. High BLACAT1 expression was correlated with high tumor grade in glioma patients. Functional assays determined that BLACAT1 promoted glioma cell proliferation, migration, invasion and epithelial-mesenchymal transition in vitro. In addition, it was demonstrated that BLACAT1 activated the Wnt/β-catenin signaling pathway. In conclusion, BLACAT1 may serve as an oncogenic lncRNA in glioma progression via activation of the Wnt/β-catenin signaling pathway. Therefore, BLACAT1 may be a novel therapeutic target for glioma treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Long non‑coding RNA BLACAT1 promotes the proliferation and invasion of glioma cells via Wnt/β‑catenin signaling

et al. 2019

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…BLACAT1, a cancer‐associated lncRNA with a length of 2616 bp, is located on in human chromosome 1q32.1 . Originally, BLACAT1 was identified in bladder cancer tissues through microarray expression profiling, and exhibited overexpression status in bladder cancer tissues compared with normal adjacent tissues .…”

Section: Discussionmentioning

confidence: 99%

“…BLACAT1, a cancer-associated lncRNA with a length of 2616 bp, is located on in human chromosome 1q32.1. 15,16 Originally, BLACAT1 was identified in bladder cancer tissues through microarray expression profiling, and exhibited overexpression status in bladder cancer tissues compared with normal adjacent tissues. 12 Subsequently, Droop et al reported that BLACAT1 was significantly overexpressed in bladder cancer tissues through analyzing TANRIC and cBioPortal databases, but significant high-expression of BLACAT1 in bladder cancer tissues and cell lines were not observed through qRT-PCR.…”

Section: Discussionmentioning

confidence: 99%

BLACAT1 predicts poor prognosis and serves as oncogenic lncRNA in small‐cell lung cancer

Chen

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Bladder cancer-associated transcript 1 (BLACAT1) is a novel identified long noncoding RNA (lncRNA) in bladder cancer, and has been suggested to function as an oncogenic lncRNA in several types of human cancer. However, its involvement in the progression of small-cell lung cancer (SCLC) remained unknown. The aim of our study was to investigate the clinical value and biological function in SCLC. In our results, BLACAT1 expression was increased in SCLC tissues and cell lines compared with paired adjacent normal tissues and bronchial epithelial cell lines, respectively. In addition, BLACAT1 high-expression was obviously associated with advanced clinical stage, large tumor size, more lymph node metastasis, present distant metastasis, and poor prognosis. Furthermore, multivariate analysis indicated that high-expression of BLACAT1 acted as an independent poor prognostic factor for overall survival in SCLC cases. The loss-of-function studies suggested that of BLACAT1 suppressed SCLC cell proliferation, migration, and invasion, and induced G0/G1 phase arrest. In conclusion, BLACAT1 is associated with the malignant status and prognosis in patients with SCLC, and functions as an oncogenic lncRNA in regulating cell proliferation and motility, suggesting BLACAT1 may act as a potential target for SCLC prevention and treatment.

show abstract

“…As shown in Table 3, limited studies have been conducted to investigate the roles of miRNAs in the resistance mechanisms to other chemotherapy drugs. MiR-155-5p, miR-34c-5p, and miR-21 were found to be related to PTX resistance; [65][66][67] miR-361-3p, miR-135a, and miR-27a affect OXA resistance; [68][69][70] miR-1284 and miR-647 regulated VCR resistance; 71,72 and miR-200a inhibited taxol resistance, while miR-361-5p suppressed docetaxel Notes: *Targets genes were confirmed by Western blotting, RT-qPCR or dual-luciferase. **Upregulation (↑) or downregulation (↓) of miRNAs enhance chemosensitivity.…”

Section: Other Single-drug Resistancementioning

confidence: 97%

<p>Research Progress in microRNA-Based Therapy for Gastric Cancer</p>

Zhao

Shi

et al. 2019

OTT

View full text Add to dashboard Cite

Gastric cancer (GC) is one of the leading causes of tumor-related mortality. In addition to surgery and endoscopic resection, systemic therapy remains the main treatment option for GC, especially for advanced-stage disease and for cases not suitable for surgical therapy. Hence, improving the efficacy of systemic therapy is still an urgent problem to overcome. In the past decade, the essential roles of microRNAs (miRNAs) in tumor treatment have been increasingly recognized. In particular, miRNAs were recently shown to reverse the resistance to chemotherapy drugs such as 5-fluorouracil, cisplatin, and doxorubicin. Synthesized nanoparticles loaded with mimics or inhibitors of miRNAs can directly target tumor cells to suppress their growth. Moreover, exosomes may serve as promising safe carriers for mimics or inhibitors of miRNAs to treat GC. Some miRNAs have also been shown to play roles in the mechanism of action of other anti-tumor drugs. Therefore, in this review, we highlight the research progress on microRNA-based therapy in GC and discuss the challenges and prospects associated with this strategy. We believe that microRNA-based therapy has the potential to offer a clinical benefit to GC patients, and this review would contribute to and motivate further research to promote this field toward this ultimate goal.

show abstract

Long noncoding RNA BLACAT1 modulates ABCB1 to promote oxaliplatin resistance of gastric cancer via sponging miR-361

Cited by 93 publications

References 22 publications

Long non‑coding RNA BLACAT1 promotes the proliferation and invasion of glioma cells via Wnt/β‑catenin signaling

Long non‑coding RNA BLACAT1 promotes the proliferation and invasion of glioma cells via Wnt/β‑catenin signaling

BLACAT1 predicts poor prognosis and serves as oncogenic lncRNA in small‐cell lung cancer

<p>Research Progress in microRNA-Based Therapy for Gastric Cancer</p>

Contact Info

Product

Resources

About